
|Articles|April 15, 2002
Comfort level of ocular allergy agent is key to patient compliance
San Antonio, TX-A treatment for seasonal allergic conjunctivitis, pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., Napa, CA), was shown to be more comfortable for patients and equally effective when used twice a day during ragweed season when compared with nedocromil sodium 2% ophthalmic solution (Alocril, Allergan, Irvine, CA). These two drugs are the two latest mast-cell stabilizers that have become commercially available to treat ocular allergies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
News from Orlando: AAO 2025 highlights research across all areas of eyecare
3
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
4
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
5